Abstract
Irinotecan (CPT-11), a semisynthetic derivative of camptothecin, is active in the treatment of non-small cell lung cancer (NSCLC). In this report we describe our experience with this drug when used as a single agent in patients with advanced NSCLC refractory to chemotherapy with platinum and taxanes. Nineteen NSCLC patients (thirteen males and six females; 53% adenocarcinoma and 26% squamous cell carcinoma) with a median age of 52 years (range 34–71) and a Karnofsky performance status of 60% (60–80%) were included in the study. At baseline, the patients had a median of two disease sites and had been treated with a median of two prior regimens. Irinotecan was given at a dose of 100 mg/m2 i.v.) weekly for 4 weeks followed by 1 week of rest. A total of 123 weekly infusions were administered, and each patient received a median of 4 weeks of treatment (range 1–32). All patients were evaluated by intention-to-treat analysis for efficacy and safety. Main toxicities reported were grade 3 neutropenia (10% of patients), diarrhea (10% of patients), and grade 4 thrombocytopenia (5% of patients). The overall clinical response rate was 16% (95% CI: 8–24) with three partial responses and 9 (47%) patients with stable disease. The median time to progression and the median survival time were 7 and 15 weeks, respectively. In conclusion, weekly irinotecan showed antitumoral activity and minimum toxicity in NSCLC patients refractory to platinum and taxanes.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, Levitan N, Gressot L, Vincent M, Burkes R, Coughlin S, Kim Y, Berille J: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18(10): 2095–2103, 2000
Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, Kalman L, Miller V, Lee JS, Moore M, Gandara D, Karp D, Vokes E, Kris M, Kim Y, Gamza F, Hammershaimb L: Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study group. J Clin Oncol 18(12): 2354–2362, 2000
Rothenberg ML, Kuhn JG, Burris HA, III, Nelson J, Eckardt JR, Tristan-Morales M, Hilsenbeck SG, Weiss GR, Smith LS, Rodriguez GI, et al.: Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol 11(11): 2194–2204, 1993
Fukuoka M, Niitani H, Suzuki A, Motomiya M, Hasegawa K, Nishiwaki Y, Kuriyama T, Ariyoshi Y, Negoro S, Masuda N, et al.: A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol 10(1): 16–20, 1992
World Health Organization: Handbook for Reporting Results of Cancer Treatment. WHO offset publications No 48, Genova, 1979
Kaplan EL, Meer P: Nonparametric estimation from incomplete observation. J Am Stat Assoc 53: 457–481, 1958
Douillard JY, Ibrahim N, Riviere A, Spaeth D, Comi P, Soussan K, Matheu-Boue A, Gaudecheau-Nanthery C, Beclesse-Caen C, Vautrin-Vandoeuvre-Les-Nancy C: A phase II study of CPT-11 in non-small cell lung cancer. Proc Am Soc Clin Oncol 14: 365, 1995
Masuda N, Fukuoka M, Negoro S, Takada Y, Sugiura T, Okashi Y, Ariyoshi Y, Nitani H, and the CPT-11 Lung Cancer Study Group West: Randomized trial comparing cisplatin (CDPP) and Irinotecan (CPT-11) versus CDPP and vindesine (VDS) versus CPT-11 alone in advanced non-small cell lung cancer (NSCLC), a multicenter phase III study. Proc Am Soc Clin Oncol 18: 459a, 1999
Masuda N, Fukuoka M, Fujita A, Kurita Y, Tsuchiya S, Nagao K, Negoro S, Nishikawa H, Katakami N, Nakagawa K, Niitani H: A phase II trial of combination of CPT-11 and cisplatin for advanced non-small-cell lung cancer. CPT-11 Lung Cancer Study Group. Br J Cancer 78(2): 251–256, 1998
Ueoka H, Kiura J, Hiraki S, Egudhi K, Okimoto N, Harita S, Marukawa M, Yonei T, Kamei H, Segawa Y, Shibayama T, Harada M: Fractionated administration of cisplatin (CDDP) and irinotecan (CPT-11) in patients with stage III B and IV non-small lung cancer (NSCLC): a phase II study. Proc Am Soc Clin Oncol 18: 525a, 1999
Mori K, Machida S, Yoshida T: A phase II study of irinotecan and infusional cisplatin with recombination human granulocyte: stimulating factor support of advanced non-small cell lung cancer ECCO 10, Vienna. Eur J Cancer 35(suppl 4): 261, 1999
Cardenal F, Domine M, Massuti B: A phase II multi-institutional study of irinotecan and cisplatin on a three week schedule in patients with advanced non-small cell lung cancer ECCO 10, Vienna. Eur J Cancer 35(suppl 4): 259, 1999
Kunitoh H, Saijo N, Nahao K: Cisplatin and irinotecan versus CDDP and vidensine in advanced (stages IIIB and IV) non-small cell lung cancer. A multicenter phase III study. ECCO 10, Vienna. Eur J Cancer 35(suppl 4): 249, 1999
Kouroussis C, Agelidou A, Apostolopoulou F, Ziotopoulos P, Georganta C, Anagnostopolou O, Polyzos A, Androulakis N, Ginopoulos P, Georgoulia V, The Greek Cooperative Group for Lung Cancer: Second-line treatment with irinotecan (CPT-11) and gemcitabine versus CPT-11 in patients with advanced NSCLC pretreated with taxanes and cisplatinum. Preliminary results of a multicenter randomized phase II study. Proc Am Soc Clin Oncol 21: 304a, 2002
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sánchez, R., Esteban, E., Palacio, I. et al. Activity of weekly irinotecan (CPT-11) in patients with advanced non-small cell lung cancer pretreated with platinum and taxanes. Invest New Drugs 21, 459–463 (2003). https://doi.org/10.1023/A:1026207519884
Issue Date:
DOI: https://doi.org/10.1023/A:1026207519884